OTCPK:SHPM.F

Stock Analysis Report

Shanghai Pharmaceuticals Holding

Executive Summary

Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People’s Republic of China.

Snowflake

Fundamentals

Undervalued established dividend payer.


Similar Companies

Share Price & News

How has Shanghai Pharmaceuticals Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.5%

OTCPK:SHPM.F

-1.2%

US Healthcare

-0.02%

US Market


1 Year Return

n/a

OTCPK:SHPM.F

-9.4%

US Healthcare

1.6%

US Market

No trading data on SHPM.F.

No trading data on SHPM.F.


Share holder returns

SHPM.FIndustryMarket
7 Day-0.5%-1.2%-0.02%
30 Day2.8%-2.2%2.7%
90 Day-3.6%-1.5%1.4%
1 Yearn/a-8.0%-9.4%3.8%1.6%
3 Year-28.8%-28.8%28.7%23.5%45.2%35.8%
5 Yearn/a62.7%53.0%61.8%44.1%

Price Volatility Vs. Market

How volatile is Shanghai Pharmaceuticals Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Shanghai Pharmaceuticals Holding undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Shanghai Pharmaceuticals Holding's share price is below the future cash flow value, and at a moderate discount (> 20%).

Shanghai Pharmaceuticals Holding's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Shanghai Pharmaceuticals Holding is good value based on earnings compared to the US Healthcare industry average.

Shanghai Pharmaceuticals Holding is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Shanghai Pharmaceuticals Holding is poor value based on expected growth next year.


Price Based on Value of Assets

Shanghai Pharmaceuticals Holding is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Shanghai Pharmaceuticals Holding expected to perform in the next 1 to 3 years based on estimates from 14 analysts?

11.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Shanghai Pharmaceuticals Holding's revenue is expected to grow by 13.2% yearly, however this is not considered high growth (20% yearly).

Shanghai Pharmaceuticals Holding's earnings are expected to grow by 11.4% yearly, however this is not considered high growth (20% yearly).

Shanghai Pharmaceuticals Holding's revenue growth is expected to exceed the United States of America market average.

Shanghai Pharmaceuticals Holding's earnings growth is positive but not above the United States of America market average.

Shanghai Pharmaceuticals Holding's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Shanghai Pharmaceuticals Holding is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Shanghai Pharmaceuticals Holding performed over the past 5 years?

10.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Shanghai Pharmaceuticals Holding's year on year earnings growth rate has been positive over the past 5 years.

Shanghai Pharmaceuticals Holding's 1-year earnings growth exceeds its 5-year average (13.9% vs 10.3%)

Shanghai Pharmaceuticals Holding's earnings growth has exceeded the US Healthcare industry average in the past year (13.9% vs 5.6%).


Return on Equity

Shanghai Pharmaceuticals Holding has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Shanghai Pharmaceuticals Holding used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

Shanghai Pharmaceuticals Holding's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Shanghai Pharmaceuticals Holding's financial position?


Financial Position Analysis

Shanghai Pharmaceuticals Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Shanghai Pharmaceuticals Holding's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Shanghai Pharmaceuticals Holding's level of debt (64.2%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (24.5% vs 64.2% today).

Debt is not well covered by operating cash flow (13.3%, less than 20% of total debt).

Shanghai Pharmaceuticals Holding earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 3.2x debt.


Next Steps

Dividend

What is Shanghai Pharmaceuticals Holding's current dividend yield, its reliability and sustainability?

3.65%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Shanghai Pharmaceuticals Holding's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

Shanghai Pharmaceuticals Holding's dividend is below the markets top 25% of dividend payers in United States of America (3.69%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are well covered by earnings (3.5x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (2.7x coverage).


Next Steps

Management

What is the CEO of Shanghai Pharmaceuticals Holding's salary, the management and board of directors tenure and is there insider trading?

3.6yrs

Average management tenure


CEO

Man Cho (58yo)

6.3yrs

Tenure

CN¥3,973,000

Compensation

Mr. Man Cho has been the President of Shanghai Pharmaceuticals Holding Co., Ltd. since June 5, 2013 and serves as its Executive Director. Mr. Cho served as vice chairman and chief executive officer of The  ...


CEO Compensation Analysis

Man's remuneration is lower than average for companies of similar size in United States of America.

Man's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.


Management Age and Tenure

3.6yrs

Average Tenure

47.5yo

Average Age

The tenure for the Shanghai Pharmaceuticals Holding management team is about average.


Board Age and Tenure

6.3yrs

Average Tenure

49.5yo

Average Age

The tenure for the Shanghai Pharmaceuticals Holding board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellCN¥820,72908 Aug 19
BlackRock, Inc.
EntityCompany
Shares431,100
Max PriceCN¥1.90
SellCN¥317,98804 Jun 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares160,447
Max PriceCN¥1.98
SellCN¥27,204,37904 Jun 19
JPMorgan Chase & Co, Private Banking and Investment Banking Investments
EntityCompany
Shares13,790,422
Max PriceCN¥1.97
BuyCN¥446,22431 May 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares225,762
Max PriceCN¥1.98
SellCN¥116,53317 Apr 19
JPMorgan Chase & Co, Private Banking and Investment Banking Investments
EntityCompany
Shares51,475
Max PriceCN¥2.26
SellCN¥196,90709 Apr 19
BlackRock, Inc.
EntityCompany
Shares88,650
Max PriceCN¥2.22
SellCN¥1,071,79002 Apr 19
BlackRock, Inc.
EntityCompany
Shares491,500
Max PriceCN¥2.18
SellCN¥1,650,27807 Mar 19
BlackRock, Inc.
EntityCompany
Shares734,800
Max PriceCN¥2.25
BuyCN¥1,124,15212 Jan 19
LSV Asset Management
EntityCompany
Shares538,500
Max PriceCN¥2.09
BuyCN¥10,628,97422 Nov 18
JPMorgan Chase & Co, Private Banking and Investment Banking Investments
EntityCompany
Shares4,350,273
Max PriceCN¥2.44
SellCN¥315,38726 Oct 18
Citigroup Inc.,Banking and Securities Investments
EntityCompany
Shares142,700
Max PriceCN¥2.21
BuyCN¥4,112,22925 Oct 18
Citigroup Inc.,Banking and Securities Investments
EntityCompany
Shares1,847,830
Max PriceCN¥2.23

Ownership Breakdown


Management Team

  • Jinqi Yu

    General Manager

    • Tenure: 0yrs
    • Compensation: CN¥754.00k
  • Bo Shen (46yo)

    CFO, VP

    • Tenure: 6.3yrs
    • Compensation: CN¥3.49m
  • Yongzhong Li (49yo)

    VP & Executive Director

    • Tenure: 6.3yrs
    • Compensation: CN¥3.94m
  • Man Cho (58yo)

    President & Executive Director

    • Tenure: 6.3yrs
    • Compensation: CN¥3.97m
  • Suet Wing Leung

    Joint Company Secretary

    • Tenure: 0.9yrs
  • Jinzhu Chen (34yo)

    Secretary of Board & Joint Company Secretary

    • Tenure: 0.08yrs

Board Members

  • Jun Zhou (50yo)

    Chairman of the Board

    • Tenure: 6.3yrs
  • Bo Shen (46yo)

    CFO, VP

    • Tenure: 6.3yrs
    • Compensation: CN¥3.49m
  • Yongzhong Li (49yo)

    VP & Executive Director

    • Tenure: 6.3yrs
    • Compensation: CN¥3.94m
  • Man Cho (58yo)

    President & Executive Director

    • Tenure: 6.3yrs
    • Compensation: CN¥3.97m
  • Jiangnan Cai (62yo)

    Independent Non-Executive Director

    • Tenure: 6.3yrs
    • Compensation: CN¥200.00k
  • Youli Xu (45yo)

    Chief Supervisor

    • Tenure: 3.3yrs
  • Liang Hong (44yo)

    Independent Non-Executive Director

    • Tenure: 6.3yrs
    • Compensation: CN¥230.00k
  • An Li (58yo)

    Non-Executive Director

    • Tenure: 6.3yrs
  • Dawei Ge

    Vice Chairman

    • Tenure: 0.3yrs
  • Zhaoyang Gu

    Independent Non-Executive Director

    • Tenure: 0yrs

Company Information

Shanghai Pharmaceuticals Holding Co., Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Shanghai Pharmaceuticals Holding Co., Ltd
  • Ticker: SHPM.F
  • Exchange: OTCPK
  • Founded: 1994
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: CN¥48.595b
  • Listing Market Cap: CN¥6.858b
  • Shares outstanding: 2.84b
  • Website: https://www.sphchina.com

Number of Employees


Location

  • Shanghai Pharmaceuticals Holding Co., Ltd
  • Shanghai Pharmaceutical Building
  • No.200 Taicang Road
  • Shanghai
  • 200020
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
601607SHSE (Shanghai Stock Exchange)YesDomestic SharesCNCNYJul 1996
601607XSSC (Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect)YesDomestic SharesCNCNYJul 1996
2607SEHK (The Stock Exchange of Hong Kong Ltd.)Foreign Shares-Foreign ListedHKHKDMay 2011
SHPM.FOTCPK (Pink Sheets LLC)Foreign Shares-Foreign ListedUSUSDMay 2011
S1RDB (Deutsche Boerse AG)Foreign Shares-Foreign ListedDEEURMay 2011
2607SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)Foreign Shares-Foreign ListedHKHKDMay 2011
2607SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)Foreign Shares-Foreign ListedHKHKDMay 2011
SHPM.YOTCPK (Pink Sheets LLC)ADR REPS SHS HUSUSDMar 2013

Biography

Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People’s Republic of Ch ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 00:25
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.